|
1
|
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
|
Nat Med
|
2007
|
13.90
|
|
2
|
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
|
Nature
|
2011
|
3.53
|
|
3
|
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
|
J Clin Oncol
|
2006
|
2.81
|
|
4
|
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
PLoS Genet
|
2013
|
2.39
|
|
5
|
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
|
Cancer Res
|
2010
|
1.90
|
|
6
|
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2011
|
1.51
|
|
7
|
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
|
J Natl Cancer Inst
|
2010
|
1.41
|
|
8
|
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.25
|
|
9
|
Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
|
Cancer Res
|
2004
|
1.18
|
|
10
|
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
|
Int J Cancer
|
2005
|
0.91
|
|
11
|
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.86
|
|
12
|
Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.
|
Eur J Hum Genet
|
2012
|
0.82
|
|
13
|
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
|
Fam Cancer
|
2012
|
0.82
|
|
14
|
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
|
Pathobiology
|
2013
|
0.80
|
|
15
|
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.79
|
|
16
|
Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
|
Psychooncology
|
2013
|
0.78
|
|
17
|
Development of a scale for assessing respondents' perceptions of health research questionnaires (the REP-HQ Scale).
|
J Clin Epidemiol
|
2012
|
0.77
|